Atlas Trials

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT06521255 · RECRUITING

Trial details

NCT number
NCT06521255
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
DLBCL
Start date
2024-05-07
Primary completion
2028-09-01
Enrollment
244

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.